RhumbLine Advisers
PBYI icon

RhumbLine Advisers’s Puma Biotechnology PBYI Stock Holding History

RhumbLine Advisers’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$339K Sell
53,036
-859
-2% -$5.54K ﹤0.01% 2851
2025
Q4 		$321K Sell
53,895
-6,106
-10% -$32.4K ﹤0.01% 2933
2025
Q3 		$319K Sell
60,001
-610
-1% -$2.59K ﹤0.01% 2952
2025
Q2 		$208K Buy
60,611
+22,316
+58% +$71.2K ﹤0.01% 3210
2025
Q1 		$113K Buy
38,295
+4
+0% +$13 ﹤0.01% 3351
2024
Q4 		$117K Sell
38,291
-8,337
-18% -$24.3K ﹤0.01% 3432
2024
Q3 		$119K Sell
46,628
-3,642
-7% -$11K ﹤0.01% 3452
2024
Q2 		$164K Buy
50,270
+48,184
+2,310% +$212K ﹤0.01% 3334
2024
Q1 		$11.1K Hold
2,086
– – ﹤0.01% 3850
2023
Q4 		$9.03K Hold
2,086
– – ﹤0.01% 3881
2023
Q3 		$5.49K Hold
2,086
– – ﹤0.01% 3965
2023
Q2 		$7.36K Buy
+2,086
New +$6.51K ﹤0.01% 4002
2022
Q2 		– Sell
-38,775
Closed -$112K – 3200
2022
Q1 		$112K Buy
38,775
+4
+0% +$10 ﹤0.01% 2870
2021
Q4 		$118K Sell
38,771
-838
-2% -$3.64K ﹤0.01% 2918
2021
Q3 		$278K Buy
39,609
+568
+1% +$4.25K ﹤0.01% 2797
2021
Q2 		$358K Sell
39,041
-2,448
-6% -$24.8K ﹤0.01% 2719
2021
Q1 		$403K Sell
41,489
-3,780
-8% -$42.2K ﹤0.01% 2585
2020
Q4 		$464K Buy
45,269
+3,260
+8% +$33K ﹤0.01% 2470
2020
Q3 		$424K Sell
42,009
-7,062
-14% -$71.9K ﹤0.01% 2362
2020
Q2 		$512K Buy
49,071
+7,300
+17% +$75.6K ﹤0.01% 2334
2020
Q1 		$353K Buy
41,771
+349
+0.8% +$3.39K ﹤0.01% 2328
2019
Q4 		$362K Buy
41,422
+893
+2% +$7.39K ﹤0.01% 2508
2019
Q3 		$436K Sell
40,529
-242
-0.6% -$2.61K ﹤0.01% 2392
2019
Q2 		$518K Buy
40,771
+2,066
+5% +$47.6K ﹤0.01% 2348
2019
Q1 		$1.5M Sell
38,705
-233
-0.6% -$7.12K ﹤0.01% 1855
2018
Q4 		$792K Buy
38,938
+12,385
+47% +$372K ﹤0.01% 2112
2018
Q3 		$1.22M Sell
26,553
-1,741
-6% -$83.9K ﹤0.01% 1914
2018
Q2 		$1.67M Buy
28,294
+133
+0.5% +$7.71K ﹤0.01% 1762
2018
Q1 		$1.92M Sell
28,161
-894
-3% -$66.9K ﹤0.01% 1633
2017
Q4 		$2.87M Sell
29,055
-5,739
-16% -$642K 0.01% 1414
2017
Q3 		$4.17M Buy
34,794
+1,061
+3% +$98.7K 0.01% 1151
2017
Q2 		$2.95M Buy
33,733
+271
+0.8% +$15.2K 0.01% 1329
2017
Q1 		$1.25M Buy
33,462
+1,429
+4% +$52.1K ﹤0.01% 1814
2016
Q4 		$983K Buy
32,033
+4,881
+18% +$211K ﹤0.01% 1859
2016
Q3 		$1.82M Sell
27,152
-206
-0.8% -$10.4K 0.01% 1463
2016
Q2 		$815K Buy
27,358
+3,907
+17% +$122K ﹤0.01% 1911
2016
Q1 		$689K Sell
23,451
-832
-3% -$37.6K ﹤0.01% 2015
2015
Q4 		$1.9M Sell
24,283
-274
-1% -$21.5K 0.01% 1389
2015
Q3 		$1.85M Sell
24,557
-497
-2% -$47K 0.01% 1367
2015
Q2 		$2.92M Sell
25,054
-235
-0.9% -$42.6K 0.01% 1161
2015
Q1 		$5.97M Buy
25,289
+3,666
+17% +$784K 0.02% 748
2014
Q4 		$4.09M Sell
21,623
-425
-2% -$94.3K 0.01% 896
2014
Q3 		$5.26M Buy
22,048
+444
+2% +$91.2K 0.02% 747
2014
Q2 		$1.43M Buy
21,604
+537
+3% +$38.2K ﹤0.01% 1593
2014
Q1 		$2.19M Sell
21,067
-857
-4% -$101K 0.01% 1279
2013
Q4 		$2.27M Buy
21,924
+750
+4% +$44K 0.01% 1294
2013
Q3 		$1.14M Buy
21,174
+1,824
+9% +$98.3K ﹤0.01% 1698
2013
Q2 		$859K Buy
+19,350
New +$682K ﹤0.01% 1873

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

RhumbLine Advisers's PBYI Position: Q1 2026 in Review

RhumbLine Advisers reduced its Puma Biotechnology (PBYI) stake by 1.6% in Q1 2026, selling an estimated $5.54K and leaving 53,036 shares worth $339K. The position accounts for ﹤0.01% of the portfolio, ranked #2851.

RhumbLine Advisers first reported a position in PBYI in Q2 2013 and has held it in 48 quarters since. The position peaked at $5.97M in Q1 2015. 157 funds tracked by Wall St. Rank hold PBYI as of Q1 2026.

  • RhumbLine Advisers held 53,036 shares of Puma Biotechnology worth $339K as of Q1 2026.
  • RhumbLine Advisers sold 859 Puma Biotechnology shares in Q1 2026, an estimated $5.54K.
  • Puma Biotechnology made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #2851 holding.
  • RhumbLine Advisers first reported a position in Puma Biotechnology in Q2 2013 and has held it in 48 quarters since.
  • RhumbLine Advisers's Puma Biotechnology position peaked at $5.97M in Q1 2015.
  • 157 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.